serious risk to public health [RSABE / ABEL]

posted by Dr_Dan  – Germany, 2014-04-07 10:35 (4464 d 02:51 ago) – Posting: # 12779
Views: 16,506

Dear Pash413
In the concept of bioequivalence bioavailability is taken as a surrogate parameter for safety and efficacy. If you observe zero concentrations throughout all the sampling points for test formulation in at-least one period in ~ 45 % subjects this would mean that in consequence this formulation would not be effective in a great portion of patients. The originator has demonstrated safety and efficacy in clinical trials. So your argumentation that zero concentrations throughout the all the sampling points for reference formulation in at-least one period in ~ 50 % subjects was shown and similar results were observed for this molecule in other literature too does not help.
If you claim that your formulation is as bad as the originator you have to proof that your observations are no artefact. If this is not possible you have to provide clinical data.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
308 visitors (0 registered, 308 guests [including 23 identified bots]).
Forum time: 13:26 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5